Shots: The US FDA has accepted the BLA and granted the PR with an anticipated PDUFA date as Jul 17, 2021 The BLA filing marks the milestone on the path […]readmore
Tags : OMS721
Shots: The ODD is based on Omeros’ P-III program assessing OMS721 in patients with HSCT-TMA. Additionally, OMS721 is being evaluated in ongoing P-III program for IgA nephropathy, and aHUS respectively […]readmore